239 related articles for article (PubMed ID: 32932935)
1. Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management.
Sadee W; Oberdick J; Wang Z
Molecules; 2020 Sep; 25(18):. PubMed ID: 32932935
[TBL] [Abstract][Full Text] [Related]
2. Ligand-Free Signaling of G-Protein-Coupled Receptors: Relevance to μ Opioid Receptors in Analgesia and Addiction.
Sadee W; McKew JC
Molecules; 2022 Sep; 27(18):. PubMed ID: 36144565
[TBL] [Abstract][Full Text] [Related]
3. Differential in vivo potencies of naltrexone and 6beta-naltrexol in the monkey.
Ko MC; Divin MF; Lee H; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2006 Feb; 316(2):772-9. PubMed ID: 16258020
[TBL] [Abstract][Full Text] [Related]
4. Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence.
Wang D; Raehal KM; Bilsky EJ; Sadée W
J Neurochem; 2001 Jun; 77(6):1590-600. PubMed ID: 11413242
[TBL] [Abstract][Full Text] [Related]
5. In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice.
Raehal KM; Lowery JJ; Bhamidipati CM; Paolino RM; Blair JR; Wang D; Sadée W; Bilsky EJ
J Pharmacol Exp Ther; 2005 Jun; 313(3):1150-62. PubMed ID: 15716384
[TBL] [Abstract][Full Text] [Related]
6. The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity.
Sirohi S; Dighe SV; Madia PA; Yoburn BC
J Pharmacol Exp Ther; 2009 Aug; 330(2):513-9. PubMed ID: 19435929
[TBL] [Abstract][Full Text] [Related]
7. Mu-opioid receptor up-regulation and functional supersensitivity are independent of antagonist efficacy.
Sirohi S; Kumar P; Yoburn BC
J Pharmacol Exp Ther; 2007 Nov; 323(2):701-7. PubMed ID: 17698975
[TBL] [Abstract][Full Text] [Related]
8. Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence.
Wang D; Raehal KM; Lin ET; Lowery JJ; Kieffer BL; Bilsky EJ; Sadée W
J Pharmacol Exp Ther; 2004 Feb; 308(2):512-20. PubMed ID: 14600246
[TBL] [Abstract][Full Text] [Related]
9. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment.
Wang D; Sun X; Sadee W
J Pharmacol Exp Ther; 2007 May; 321(2):544-52. PubMed ID: 17267582
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and characterization of 6beta-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes.
Pelotte AL; Smith RM; Ayestas M; Dersch CM; Bilsky EJ; Rothman RB; Deveau AM
Bioorg Med Chem Lett; 2009 May; 19(10):2811-4. PubMed ID: 19364645
[TBL] [Abstract][Full Text] [Related]
11. In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone.
Porter SJ; Somogyi AA; White JM
Addict Biol; 2002 Apr; 7(2):219-25. PubMed ID: 12006217
[TBL] [Abstract][Full Text] [Related]
12. The role of opioid antagonist efficacy and constitutive opioid receptor activity in the opioid withdrawal syndrome in mice.
Navani DM; Sirohi S; Madia PA; Yoburn BC
Pharmacol Biochem Behav; 2011 Oct; 99(4):671-5. PubMed ID: 21736895
[TBL] [Abstract][Full Text] [Related]
13. Comparison of naltrexone, 6alpha-naltrexol, and 6beta-naltrexol in morphine-dependent and in nondependent rhesus monkeys.
Li JX; McMahon LR; France CP
Psychopharmacology (Berl); 2008 Jan; 195(4):479-86. PubMed ID: 17874317
[TBL] [Abstract][Full Text] [Related]
14. 6beta-naltrexol preferentially antagonizes opioid effects on gastrointestinal transit compared to antinociception in mice.
Yancey-Wrona JE; Raymond TJ; Mercer HK; Sadée W; Bilsky EJ
Life Sci; 2009 Sep; 85(11-12):413-20. PubMed ID: 19583969
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel "almost neutral" micro-opioid receptor antagonist in CHO cells expressing the cloned human mu-opioid receptor.
Sally EJ; Xu H; Dersch CM; Hsin LW; Chang LT; Prisinzano TE; Simpson DS; Giuvelis D; Rice KC; Jacobson AE; Cheng K; Bilsky EJ; Rothman RB
Synapse; 2010 Apr; 64(4):280-8. PubMed ID: 19953652
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the opioid receptor antagonist properties of naltrexone and 6 beta-naltrexol in morphine-naïve and morphine-dependent mice.
Divin MF; Holden Ko MC; Traynor JR
Eur J Pharmacol; 2008 Mar; 583(1):48-55. PubMed ID: 18275956
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats.
Schwienteck KL; Faunce KE; Rice KC; Obeng S; Zhang Y; Blough BE; Grim TW; Negus SS; Banks ML
Neuropharmacology; 2019 May; 150():200-209. PubMed ID: 30660628
[TBL] [Abstract][Full Text] [Related]
18. Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor.
Divin MF; Bradbury FA; Carroll FI; Traynor JR
Br J Pharmacol; 2009 Apr; 156(7):1044-53. PubMed ID: 19220294
[TBL] [Abstract][Full Text] [Related]
19. 6β-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study.
Yancey-Wrona J; Dallaire B; Bilsky E; Bath B; Burkart J; Webster L; Magiera D; Yang X; Phelps M; Sadee W
Pain Med; 2011 Dec; 12(12):1727-37. PubMed ID: 22123184
[TBL] [Abstract][Full Text] [Related]
20. Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.
Largent-Milnes TM; Guo W; Wang HY; Burns LH; Vanderah TW
J Pain; 2008 Aug; 9(8):700-13. PubMed ID: 18468954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]